This compound is utilized in the field of targeted protein degradation, specifically as a component of PROTAC (Proteolysis Targeting Chimeras) molecules. It is designed to selectively bind to BRD4, a protein involved in the regulation of gene expression, particularly in cancer cells. By incorporating this ligand into a PROTAC, it facilitates the recruitment of an E3 ubiquitin ligase to BRD4, marking it for degradation by the proteasome. This approach is being explored as a potential therapeutic strategy in oncology, aiming to disrupt the function of BRD4 in cancer progression and drug resistance. Its application is significant in research focused on developing novel treatments for cancers where BRD4 plays a critical role, such as certain types of leukemia and solid tumors.